Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 7/20 | 0.57 |
| ▸ | EGFR | P00533 | 7/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | DHFR | P00374 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17528544 | 0.88 | EGFR (0.60) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL12620147 | 0.77 | TYMS (0.61) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL1154407 | 0.77 | DHFR (0.75) | DHFR | |
| SCHEMBL17500020 | 0.75 | EGFR (0.59) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL12391891 | 0.75 | EGFR (0.63) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL1994777 | 0.73 | TYMS (1.00) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL17528504 | 0.73 | EGFR (0.57) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL1923985 | 0.71 | EGFR (0.63) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL6854925 | 0.71 | GAA (0.51) | PDGFRBKDRFLT3CYP1A2CYP3A4 | |
| SCHEMBL5442696 | 0.68 | DHFR (0.45) | DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-07 | — | — | US | disclosed |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-11-26 | — | — | US | disclosed |
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-26 | — | — | US | disclosed |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
| US-10233194-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Duquesne Unversity of the Holy Spirit (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2016022890-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | TYMS 5/4885EGFR 1764/4885PDGFRB 997/4885 |
| US-10233194-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | TYMS 6/4885EGFR 1982/4885PDGFRB 1337/4885 |
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, TYMP, TPMT | TYMS 4/4885EGFR 2152/4885PDGFRB 1339/4885 |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | TYMS 5/4885EGFR 1662/4885PDGFRB 984/4885 |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | TYMS 6/4885EGFR 1982/4885PDGFRB 1337/4885 |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | TYMS 5/4885EGFR 1662/4885PDGFRB 984/4885 |
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, TYMP, TPMT | TYMS 4/4885EGFR 2152/4885PDGFRB 1339/4885 |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | TYMS 5/4885EGFR 1764/4885PDGFRB 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.